CVS Health Corporation is rated a Buy with a strong turnaround driving industry-leading results. Learn more about CVS stock ...

CVS Health’s narrative has shifted with a slightly higher fair value estimate, nudging from about $91.50 to roughly $92.40 ...

CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady ...

The healthcare giant expects its turnaround efforts to pay off as it raised its full-year outlook and expects that momentum ...

Fintel reports that on December 12, 2025, Bernstein maintained coverage of CVS Health (NYSE:CVS) with a Market Perform ...

CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

It’s part of a larger battle between Louisiana officials and big health care companies over prescription drug prices.

CVS Health raises its 2025 revenue outlook as Bank of America highlights stronger margins, new tech investments, and momentum ...

Fintel reports that on December 10, 2025, Morgan Stanley maintained coverage of CVS Health (NYSE:CVS) with a Overweight ...

In addition to the updates for 2025, CVS offered its first look at expected earnings for 2026. The company said it ...